Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some core microbiology concepts (beta-lactamase inhibition, ampicillin cell wall mucopeptide biosynthesis inhibition, and limited organism/indication-aligned themes) are supported, but many extracted claims overreach beyond what is explicitly stated in the provided label text (notably specific organism examples, mechanism details like PBPs/peptidoglycan cross-linking/lysis chain, and multiple indication and adverse reaction examples).
Category Scores
Accurate Statements
Ampicillin and sulbactam is a combination antibiotic consisting of ampicillin and sulbactam.
DESCRIPTION: injectable antibacterial combination of ampicillin sodium and sulbactam sodium.
Ampicillin is a beta-lactam antibiotic.
MICROBIOLOGY: described as a beta-lactam antibacterial (inhibition of cell wall mucopeptide biosynthesis; degraded by beta-lactamases).
Sulbactam is a beta-lactamase inhibitor.
MICROBIOLOGY + DESCRIPTION: sulbactam is described as a beta-lactamase inhibitor that irreversibly inhibits beta-lactamases and restores/extends ampicillin activity.
Ampicillin and sulbactam is designed to target bacteria that produce beta-lactamase enzymes.
MICROBIOLOGY: beta-lactamases degrade beta-lactam antibacterials; sulbactam restores/extends ampicillin activity against beta-lactamase producing strains.
Beta-lactamase enzymes are produced by some bacteria as a defense mechanism against antibiotics.
MICROBIOLOGY: beta-lactamases found in microorganisms resistant to penicillins/cephalosporins; beta-lactamase role in resistance.
Beta-lactamase enzymes can break down beta-lactam antibiotics such as ampicillin, rendering them ineffective.
MICROBIOLOGY: ampicillin degraded by beta-lactamases; spectrum does not normally include organisms that produce these enzymes.
Sulbactam prevents beta-lactamase from breaking down the ampicillin molecule.
MICROBIOLOGY: sulbactam irreversibly inhibits beta-lactamases and restores ampicillin activity; formulation extends ampicillin spectrum.
Ampicillin targets a wide range of bacteria, including Gram-positive bacteria such as Staphylococcus aureus.
MICROBIOLOGY: lists Staphylococcus aureus in Gram-Positive bacteria.
Ampicillin targets a wide range of bacteria, including Gram-positive bacteria such as Streptococcus pneumoniae.
MICROBIOLOGY: lists Streptococcus pneumoniae.
Ampicillin targets a wide range of bacteria, including Gram-negative bacteria such as Escherichia coli.
MICROBIOLOGY: lists Escherichia coli.
Ampicillin targets a wide range of bacteria, including anaerobic bacteria such as Bacteroides fragilis.
MICROBIOLOGY: Anaerobes list includes Bacteroides species including B. fragilis.
Ampicillin works by inhibiting the synthesis of the bacterial cell wall.
MICROBIOLOGY: acts through inhibition of cell wall mucopeptide biosynthesis.
Sulbactam prevents the breakdown of ampicillin.
MICROBIOLOGY: beta-lactamase inhibition restores/extends ampicillin activity; formulation extends spectrum to include bacteria normally resistant to it.
Ampicillin and sulbactam is effective against antibiotic-resistant bacteria that produce beta-lactamase enzymes.
MICROBIOLOGY + INDICATIONS: sulbactam restores ampicillin activity against beta-lactamase producing strains; indications specify beta-lactamase producing strains.
Potential side effects of ampicillin and sulbactam include diarrhea.
PRECAUTIONS: states diarrhea is a common problem caused by antibacterial.
Unsupported Statements
Sulbactam works by binding to beta-lactamase enzymes.
MICROBIOLOGY describes irreversibly inhibiting beta-lactamases but the provided label text does not explicitly state 'binding'.
Ampicillin targets a wide range of bacteria, including Gram-positive bacteria such as Enterococcus faecalis.
MICROBIOLOGY lists 'Streptococcus faecalis (Enterococcus)' but does not explicitly state 'Enterococcus faecalis'.
Ampicillin targets a wide range of bacteria, including Gram-negative bacteria such as Klebsiella pneumoniae.
Provided MICROBIOLOGY Gram-negative list states 'Klebsiella species (all known strains are beta-lactamase producing)'; 'K. pneumoniae' is referenced in INDICATIONS, not explicitly in the MICROBIOLOGY organism list as written.
Ampicillin targets a wide range of bacteria, including Gram-negative bacteria such as Pseudomonas aeruginosa.
Pseudomonas is mentioned only in PRECAUTIONS as a potential superinfection; not listed in MICROBIOLOGY or INDICATIONS as a susceptible organism.
Ampicillin targets a wide range of bacteria, including anaerobic bacteria such as Fusobacterium nucleatum.
Fusobacterium nucleatum is not listed in the provided MICROBIOLOGY Anaerobes section.
Ampicillin targets a wide range of bacteria, including anaerobic bacteria such as Peptostreptococcus magnus.
MICROBIOLOGY lists 'Peptostreptococcus species' but does not specify 'Peptostreptococcus magnus'.
Ampicillin binds to penicillin-binding proteins (PBPs) on the bacterial cell wall.
The provided MICROBIOLOGY text describes inhibition of cell wall mucopeptide biosynthesis and does not mention PBPs.
Ampicillin prevents the cross-linking of peptidoglycan layers.
Cross-linking/peptidoglycan cross-linking is not stated in the provided MICROBIOLOGY text.
Prevention of peptidoglycan cross-linking leads to weakening of the bacterial cell wall.
This causal sequence is not stated in the provided MICROBIOLOGY text.
Weakening of the bacterial cell wall leads to bacterial cell lysis and death.
The provided MICROBIOLOGY text states bactericidal action and inhibition of biosynthesis but does not present the explicit 'weakening -> lysis and death' sequence.
Sulbactam works by inhibiting the production of beta-lactamase enzymes.
Label states irreversibly inhibition of beta-lactamases; it does not state sulbactam inhibits production.
Sulbactam binds to the beta-lactamase enzyme.
Provided label text describes irreversibly inhibited beta-lactamases, not 'binding'.
Ampicillin and sulbactam provides a dual approach to targeting bacteria.
MICROBIOLOGY supports beta-lactamase inhibitor and broad-spectrum antibacterial properties, but does not explicitly describe a 'dual approach' phrasing.
Ampicillin and sulbactam is used to treat skin and soft tissue infections such as cellulitis, abscesses, and wound infections.
INDICATIONS section provided lists 'Skin and Skin Structure Infections' and specific organisms, but does not provide the example conditions 'cellulitis, abscesses, and wound infections' in the provided text.
Ampicillin and sulbactam is used to treat respiratory tract infections such as pneumonia, bronchitis, and sinusitis.
The provided INDICATIONS section does not list respiratory tract conditions (pneumonia/bronchitis/sinusitis).
Ampicillin and sulbactam is used to treat urinary tract infections such as cystitis, pyelonephritis, and prostatitis.
The provided INDICATIONS section does not list urinary tract conditions (cystitis/pyelonephritis/prostatitis).
Ampicillin and sulbactam is used to treat gastrointestinal infections such as gastroenteritis, cholecystitis, and appendicitis.
The provided INDICATIONS section lists 'Intra-Abdominal Infections' with specified organisms but does not list 'gastroenteritis/appendicitis/cholecystitis' as examples.
Ampicillin and sulbactam is effective against some antibiotic-resistant bacteria.
MICROBIOLOGY supports activity extension/restoration against beta-lactamase producing strains, but the general phrase 'some antibiotic-resistant bacteria' is not explicitly stated.
Potential side effects of ampicillin and sulbactam include allergic reactions.
ADVERSE REACTIONS section excerpt provided does not list specific adverse reactions; 'allergic reactions' is not supported by the supplied text.
Potential side effects of ampicillin and sulbactam include nausea.
Nausea is not mentioned in the provided label text.
Potential side effects of ampicillin and sulbactam include vomiting.
Vomiting is not mentioned in the provided label text.
Contradictions
Important Omissions
The provided response did not address that indications depend on infections due to susceptible strains of designated microorganisms and, for listed conditions, beta-lactamase producing strains (per INDICATIONS and USAGE).
Importance:
Moderate
The provided response did not mention that therapy should be based on culture and susceptibility testing (and empiric selection considerations) as described in INDICATIONS and USAGE.
Importance:
Moderate
The provided response did not include key safety contraindication content (e.g., serious hypersensitivity history and cholestatic jaundice/hepatic dysfunction) from CONTRAINDICATIONS.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Overstated organism/indication examples and mechanistic claims that are not supported by the provided label text could mislead interpretation of spectrum and use; adverse reaction claims are also partly unsupported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple extracted claims (specific organism/condition examples, several detailed mechanism statements, and certain adverse reaction examples) are not explicitly supported by the provided label text.
Suggested Improvement
Limit claims to wording and examples explicitly present in DESCRIPTION, INDICATIONS AND USAGE, MICROBIOLOGY, PRECAUTIONS, and the provided ADVERSE REACTIONS excerpt; avoid unsupported mechanistic detail (e.g., PBPs/cross-linking/lysis sequence) and unsupported adverse reaction examples (allergic reactions, nausea, vomiting) unless those reactions are stated in the supplied label text.